Latest filing published 21 Dec 2022 for Biocryst Pharmaceuticals INC.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michael L. Jones: trading record in brief
Michael L. Jones (chief executive) discloses dealings in Biocryst Pharmaceuticals Inc to SEC (Form 4). Over a trading history stretching from 18 March 2021 to 19 December 2022, the count stands at 8 filings.
Sales make up the whole of the open-market record (3 sales, €147k). Outside the open market, there are 2 share grants and 3 option exercises. So far in 2022, the count stands at no purchases and 3 sales.
The record was last updated on 21 December 2022 with a share grant in Biocryst Pharmaceuticals Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Michael L. Jones
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,900 shares0Common StockSEC:0001127602-22-028078:0
- 445 shares@ US$10.9017.5% of flowCommon StockSEC:0001127602-22-027870:0
- 8,600 shares@ US$1.4245.1% of flowCommon StockSEC:0001127602-22-026834:0
- 2,300 shares@ US$4.7337.4% of flowCommon StockSEC:0001127602-22-008047:0
- 5,850 shares0Common StockSEC:0001127602-21-031141:0
5 of 5 declarations
